The role of intravenous iron in anemia management and transfusion avoidance. (öffnet neues Fenster)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Quelle‎: Transfusion 2008;48(5):988-1000.

Indiziert‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (öffnet neues Fenster)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (öffnet neues Fenster)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Quelle‎: BJU Int 2011;108(10):1582-7.

Indiziert‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (öffnet neues Fenster)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (öffnet neues Fenster)

Lepor H, Lipkin M, Slova D.

Quelle‎: Urology 2010;75(6):1424-8.

Indiziert‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (öffnet neues Fenster)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (öffnet neues Fenster)

Nieder AM, Rosenblum N, Lepor H.

Quelle‎: Urology 2001;57(4):737-41.

Indiziert‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (öffnet neues Fenster)